Business
Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancers
Presentations to highlight role of Guardant liquid biopsy tests and real-world data to help identify actionable biomarkers and predict disease recurrence and
About this update from Guardant Health, Inc.
[{"type":"text","content":"\nPresentations to highlight role of Guardant liquid biopsy tests and real-world data to help identify actionable biomarkers and predict disease recurrence and response to therapy\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the ASCO 2023 Gastrointestinal Cancers Symposium, January 19-21 in San Francisco.\n\nThe 10 poster presentations highlight the use of the Guardant360® and Guardant RevealTM blood tests and the GuardantINFORMTM real-world evidence dataset to identify critical biomarkers and acquired co-mutations, track associated treatment patterns and clinical outcomes, and predict disease recurrence from minimal residual disease (MRD) detection.\n\n“We look forward to sharing new data at the ASCO GI Symposium demonstrating the utility of our blood tests and real-world data to increase the understanding of potential biomarker targets for therapy, as well as predictive markers for treatment resistance and disease recurrence in patients with gastrointestinal cancers,” said Helmy Eltoukhy, Guardant Health co-CEO. “The presentations will show how data from circulating tumor DNA tests provide critical insights that can contribute to the development of more effective therapies and better-informed patient care.”\n\nFull List of Guardant Health Presentations\n\nGuardant360\n\n\nctDNA-based fusion detection for advanced colorectal cancer with a partner-agnostic assay (abstract 186)\n\n\nFGFR2-amplified gastroesophageal adenocarcinoma is a distinct genomic class: Lessons learned from a liquid biopsy platform (abstract 429)\n\n\nA plasma-based analysis and genomic landscape of patients with high tumor mutational burden (TMB-H), microsatellite stable (MSS) colorectal cancer (CRC) (abstract 249)\n\n\nFrequency and outcomes of BRAF alterations identified by liquid biopsy in metastatic non-colorectal gastrointestinal cancers (abstract 808)\n\n\nThe identification of reversion mutations in patients with advanced pancreatic cancer and germline or somatic BRCA or PALB2 variants who were treated with maintenance rucaparib (abstract 734)\n\n\nCirculating tumor DNA-based genomic landscape of KRAS wild-type pancreatic adenocarcinoma (abstract 747)\n\n\nEffect of EGFR and ERBB2 amplifications a...